Background: Extracellular matrix degradation, mediated by the urokinase plasminogen activation (uPA) system, is a critical step in tumor invasion and metastasis. High tumor levels of uPA and its inhibitor PAI-1 have been correlated with poor cancer prognosis. We examined four single nucleotide polymorphisms (SNPs) with a potential effect on expression of genes in the uPA system for their role in colorectal cancer susceptibility and prognosis.
introduction Extracellular matrix (ECM) degradation mediated by the urokinase plasminogen activation (uPA) system is an important mechanism involved in both physiological and pathological tissue remodeling [1] [2] [3] . Increased activity of the uPA system has been linked to tumor invasion and metastasis as well as to poor cancer prognosis [1, [3] [4] [5] . In addition to the ligand uPA, the uPA sytem includes the receptor uPAR, and two inhibitors, PAI-1 and PAI-2. uPA/uPAR promotes ECM degradation by converting plasminogen to plasmin, a proteinase that can activate certain matrix metalloproteinases and degrade most components of ECM [1] [2] [3] . The uPA system can also regulate cell adhesion and migration through the interaction with vitronectin (VTN) and adhesion receptors of the integrin family. Finally, uPA/uPAR can initiate signal transduction and induce chemotaxis. The effect of uPA/uPAR on plasminogen activation is regulated by PAI-1 and PAI-2.
PAI-1 can also modulate the interaction between uPAR and VTN and some integrins.
Tumor tissue levels of the components of the uPA system have been implicated as promising prognostic markers in a wide range of malignancies, including colorectal cancer (CRC) [1, [4] [5] [6] [7] . Expression levels of the uPA system components have been shown to be very low in normal colorectal mucosa, but high in invasive carcinomas [1] . Additionally, high plasma uPAR and PAI-1 levels have been associated with worse survival in patients with CRC [8, 9] . However, these two studies did not measure the protein levels in the tumor tissues and other studies have found no correlation between the plasma and the tumor tissue levels of the components of the uPA system in colorectal and breast cancer patients [10, 11] .
Expression of the components of the uPA system can be upregulated by several hormones, growth factors and cytokines [1, 5] . Since single nucleotide polymorphisms (SNPs) located within the promoter or other regulatory regions of the genes in the uPA system may affect the expression of the gene or the protein, genotyping of these SNPs could provide a simple method to predict the risk and the prognosis of cancer. We selected a subset of SNPs from the genes in the uPA system and their substrates and examined whether they confer any CRC risk or if they could serve as prognostic biomarkers. We genotyped these SNPs in a Swedish incident CRC series, from which data of Dukes' stage and long-term survival were available.
material and methods population
The analyses were performed on genomic DNA from 308 Swedish CRC cases together with 585 controls. The cases, with the age-and gender-matched controls, were drawn from the population-based Västerbotten intervention project and the mammary screening project, which contain blood samples collected between October 1987 and April 2002 from an ethnically homogenous population living in a geographically defined region in North Sweden [12] . Prospective cases were identified from the cohorts by record linkage to the regional cancer registry. The controls were selected from the same cohort as the corresponding case. They were matched with the case by age at baseline (+/-6 months) and the time of sampling (+/-2 months). The controls had to be alive at the time of diagnosis of the corresponding case and without any previous cancer diagnosis, except carcinoma in situ of cervix uteri. The blood samples were stored at -80°C until the time of sample selection and DNA isolation for genotyping analyses. Clinical data for the CRC cases were retrieved from the registry managed by the Northern Sweden Collaborative Group for Colorectal Diseases (Table 1) . Information about the date of death was collected from the Swedish population register, with a follow-up until September 2006. The study was approved by the ethical committee of Karolinska Institute Syd and Umeå University.
selection of SNPs
The SNPs were selected for the genotyping analyses based on functional considerations and our previous study on their effect on breast cancer susceptibility and prognosis (manuscript submitted). Functional data were available for the PAI-1 (official HUGO name: SERPINE) rs1799889 -675 4G/5G SNP [13] [14] [15] [16] . Additionally, the Transcription Element Search System (TESS) [17] and TRANSFAC [18] databases were used to predict the effect of the promoter SNPs on transcription factor binding sites. In the case of coding SNPs, the PolyPhen website tool [19] was used to predict the impact of the amino acid substitution on the structure and function of the protein. In addition to the PAI-1 SNP, we selected for our analyses the following SNPs: uPA (PLAU) rs2227564 + 54 C/T in exon 6 (amino acid change Leu/Pro); uPAR (PLAUR) rs344781 -516 A/G; and VTN rs704 + 220 C/T in exon 7 (Thr/Met).
genotyping
The selected SNPs were genotyped by Taqman assay by design; primer and probe sequences are available upon request. Taqman probes were ordered from Applied Biosystems (CA, USA). The results were read in ABI PRISM 7900 HT Sequence Detection System and the genotypes were assigned automatically by the software SDS2.1.
statistical analyses
The observed genotype frequencies in the controls were tested for Hardy-Weinberg equilibrium (HWE) and the difference between the observed and expected frequencies was tested for significance using the v 2 test. Statistical significance for the differences in the genotype frequencies between the CRC cases and controls was determined by using the v 2 test. Odds ratios (ORs) and 95% confidence intervals (CIs)
for associations between genotypes and CRC and tumor characteristics were calculated by conditional logistic regression. For a polymorphism with a risk genotype frequency between 10% and 20%, our study had greater than 80% power to detect an OR of 1.8 to 1.6. The Kaplan-Meier method was used to estimate the survival probabilities, and the log-rank test was used to test differences between subgroups. Statistical analyses were performed using SPSS, Version 14.
results no association with CRC susceptibility or Dukes' stage Genotype distribution in controls followed HWE for all SNPs genotyped in this study. As shown in 
association with survival
The overall survival after 100 months follow-up time was 84% for patients with Dukes' stage A tumors, decreasing with the severity of the disease (Dukes' stage B, 64%; C, 50%; D, 8%) ( Figure 1) . Stratification of the cases by the PAI-1 genotype showed a better survival for 5G/5G genotype carriers than for carriers of the other genotypes (5G/5G vs 4G/4G, P = 0.058; 5G/5G vs 4G/5G, P = 0.025; see Figure 2A ), especially for patients with Dukes' stage A or B tumors (5G/5G vs 4G/4G, P = 0.023; 5G/5G vs 4G/5G, P = 0.015; see Figure 2B ). The difference between the heterozygous 4G/5G genotype carriers and the homozygous 4G/4G genotype carriers among all patients or among patients with Dukes' stage A or B tumors was not statistically 
discussion
Accumulating evidence suggest that increased activity of the uPA system associates with increased tumor invasion, metastasis and bad prognosis for cancer patients, also with CRC [1, [3] [4] [5] . So far, only a few, rather small studies focusing on uPA and PAI-1 SNPs have been published on CRC [20, 21] , although SNPs in the regulatory regions of the genes may affect gene expression and further protein expression [13] [14] [15] [16] . None of the previous studies have contained data of survival. Our aim was to evaluate the impact of SNPs in several genes of the uPA system on the susceptibility to and prognosis of CRC. The SNPs in the uPA, uPAR, PAI-1 and VTN genes genotyped by us were not associated with the risk of CRC. However, the PAI-1 5G/5G genotype carriers had better survival than 5G/4G or 4G/4G carriers when the patients had Dukes' stage A or B tumors. The present study was particularly suitable for survival analysis, because all patients were sampled before the diagnosis of CRC, independently of their genotype. The follow-up time was up to 16 years, allowing analysis of long-term survival. In Sweden, there have been no large changes in the clinical management of CRC since 1990, thus excluding the effects of genotype-specific responses to different treatments on survival. Additionally, the genotype distribution was similar over the follow-up time. Because data of Dukes' stage of the tumors were available, subdivision of the patients according to the severity of the disease based on the traditional prognostic marker was also possible. In our study more patients with Dukes' stage A tumors was observed than expected. The participation rate in the Västerbotten Intervention Project was 60-70% of the population. It is possible that there was a selection bias in the recruited population, as individuals aware of their health may have been more prone to participate.
As in all case-control association studies, analysis of multiple SNPs represents a statistical multiple comparison problem. Although there are several methods for handling multiple comparisons in molecular epidemiological studies, no standard approach has been universally adopted [22] . It is also unclear how the likely biological relevance of an SNP should be taken into account. In our study, the statistical significance of the observed association between the PAI-1 4G/5G SNP and survival was not overwhelming. However, there is strong evidence that this SNP is biologically significant [13] [14] [15] [16] 23] .
The better survival of the PAI-1 5G/5G genotype carriers compared to the 4G allele carriers may be explained by the reported effect of the 4G/5G SNP on free plasma PAI-1 levels [13] [14] [15] . We observed the better survival only in patients with Dukes' stage A or B tumors, possible because in patients with more severe disease many other factors contributing to poor survival may mask the positive effect of an individual SNP. Both the 4G and the 5G alleles bind a transcriptional The number of cases may vary because of some missing data. original article Annals of Oncology activator, whereas the 5G allele also binds a repressor protein [13, 14] . As a result, the 4G allele shows an enhanced transcription, and the plasma PAI-1 levels in 4G/4G homozygotes are about 25% higher than in 5G/5G homozygotes [14] . Recently, the 4G/5G polymorphism has been shown to be located within the functional binding elements for the transcription factors Smad and NF-jB, which mediate the effects of the two known inducers of the PAI-1 expression, TGFb and TNFa, respectively [16, 23] .
The relationship of the SNPs in the genes of the uPA system and the prognosis of CRC has been studied only for the PAI-1 4G/5G SNP [20] . In that study, the 4G/4G genotype was associated with more advanced tumors (Dukes' stage C and D) and the 5G/5G genotype with Dukes' stage A and B tumors. Also in our study the 4G/4G genotype was more common in patients with Dukes' stage C and D tumors than the 5G/5G genotype. In patients with Dukes' stage A and B tumors, 5G/5G was the more common one. However, the association was not statistically significant. Nor were there any statistically significant associations between the other SNPs studied and Dukes' stage.
In our survival analysis, the PAI-1 -675 5G/5G genotype was associated with a good survival in patients with Dukes' stage A and B tumors. It has been discussed that new prognostic markers would be needed, especially to identify patients with Dukes' stage B tumors with poor survival, who would benefit most from adjuvant therapy [9] . Both uPA and uPAR levels have been suggested to predict survival in patients with Dukes' stage B tumors [9, 24] . Our study and that conducted by Loktionov et al [20] add PAI-1 to the list of putative survival markers for patients with Dukes' stage B tumors.
Our result of finding no association of the studied polymorphisms with the risk of CRC is concordant with the few previously published studies [20, 21] . A small study in 40 CRC patients did not find any association between uPA +54 C/T SNP and CRC risk [21] , although the CC genotype was associated with higher levels of uPA antigens in the CRC samples [25] . For PAI-1, the 4G/5G SNP was not associated with the risk of CRC in a study of 206 CRC patients and 355 healthy controls [20] . The uPAR -516 A/G SNP, located within one of the PEA3/ets transcriptional silencing elements in the uPAR promoter, mediates the effects of integrin b3 on uPAR expression [26, 27] . This may explain the small, non-significant protective effect of the SNP on CRC risk. Taken together, these results suggest that the SNPs in the genes of the uPA system may not be important in the early stage of cancer development. The contributory effect of PAI-1 4G/5G SNP on plasma PAI-1 levels has been evaluated to be 3%, but only among women [28] . With our sample size of 308 CRC patients and 585 controls and the risk genotype frequency of 20%, we had a power of 80% to detect an OR of 1.6. Thus, only major effects of the studied SNPs on the CRC risk could be excluded.
In conclusion, genetic variation may affect prognosis of CRC patients [29] . Our results suggest a better survival for the carriers of the PAI-1 -675 5G/5G genotype than for the carriers of the other genotypes, especially for patients with Dukes' stage A and B tumors. To evaluate the significance of (A) Among all CRC patients, the 5G/5G carries had a better overall survival compared to the 4G/4G carriers (P = 0.058) and to the 4G/5G carriers (P = 0.025). (B) Among patients with Dukes'stage A and B tumors, the 5G/5G carriers had a better overall survival compared to the 4G/4G carriers (P = 0.023) and to the 4G/5G carriers (P = 0.015). (C) Among patients with Dukes'stage C and D tumors, the genotype did not affect survival. See Table 2 for the number of cases with each genotype. references
